Increased Angiopoietin-1 and -2 levels in human vitreous are associated with proliferative diabetic retinopathy

PLoS One. 2023 Jan 20;18(1):e0280488. doi: 10.1371/journal.pone.0280488. eCollection 2023.

Abstract

Background: Diabetic retinopathy is a frequent complication of diabetes mellitus and a leading cause of blindness in adults. The objective of this study was to elucidate the diabetic retinopathy pathophysiology in more detail by comparing protein alterations in human vitreous of different diabetic retinopathy stages.

Methods: Vitreous samples were obtained from 116 patients undergoing pars plana vitrectomy. Quantitative immunoassays were performed of angiogenic factors (VEGF-A, PIGF, Angiopoietin-1, Angiopoietin-2, Galectin-1) as well as cytokines (IL-1β, IL-8, IFN-γ, TNF-α, CCL3) in samples from control patients (patients who don't suffer from diabetes; n = 58) as well as diabetes mellitus patients without retinopathy (n = 25), non-proliferative diabetic retinopathy (n = 12), and proliferative diabetic retinopathy patients (n = 21). In addition, correlation analysis of protein levels in vitreous samples and fasting glucose values of these patients as well as correlation analyses of protein levels and VEGF-A were performed.

Results: We detected up-regulated levels of VEGF-A (p = 0.001), PIGF (p<0.001), Angiopoietin-1 (p = 0.005), Angiopoietin-2 (p<0.001), IL-1β (p = 0.012), and IL-8 (p = 0.018) in proliferative diabetic retinopathy samples. Interestingly, we found a strong positive correlation between Angiopoietin-2 and VEGF-A levels as well as a positive correlation between Angiopoietin-1 and VEGF-A.

Conclusion: This indicated that further angiogenic factors, besides VEGF, but also pro-inflammatory cytokines are involved in disease progression and development of proliferative diabetic retinopathy. In contrast, factors other than angiogenic factors seem to play a crucial role in non-proliferative diabetic retinopathy development. A detailed breakdown of the pathophysiology contributes to future detection and treatment of the disease.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Angiopoietin-1 / metabolism
  • Angiopoietin-2 / metabolism
  • Cytokines / metabolism
  • Diabetes Mellitus* / metabolism
  • Diabetic Retinopathy* / diagnosis
  • Female
  • Humans
  • Interleukin-8 / metabolism
  • Placenta Growth Factor / metabolism
  • Vascular Endothelial Growth Factor A / metabolism
  • Vitrectomy
  • Vitreous Body / metabolism

Substances

  • Angiopoietin-2
  • Angiopoietin-1
  • Vascular Endothelial Growth Factor A
  • Interleukin-8
  • Placenta Growth Factor
  • Cytokines

Grants and funding

S.C.J. received funding from the Bayer Vital GmbH for this work. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. There was no additional external funding received for this study.